This article is more than 5 years old. Information may no longer be current.
2CTech begins nanoparticle retina treatment trials
Click Here to Manage Email Alerts
2CTech Inc. has initiated a clinical trial program for quantum dots, a nanoparticle technology treatment candidate for retinal diseases, according to a press release.
The study will test the safety and efficacy of quantum dots – semiconductor crystalline structures that absorb light and generate a dipole electrical field, stimulating the retina cells – in retinitis pigmentosa patients.
“We are more than gratified to have reached this point in the development of this unique and high-potential therapeutic approach for what are otherwise debilitating retinal diseases and conditions,” 2CTech President and CEO Jim Taylor said. “The opportunity to provide meaningful benefits for patients afflicted with RP is something that energizes everyone associated with this important program.”
Previous preclinical and first-in-human trials showed strong evidence of safety and indications of meaningful vision enhancement following a one-time injection of quantum dots into the vitreous, the release said.